No, according to relevant public information, Taishengqi Patient Assistance Project Office received feedback, and some social workers pretended to be the staff of Taishengqi Patient Assistance Project Office of China Cancer Foundation, which caused misunderstanding among patients and had a negative impact on the project. Taishengqi (atilizumab injection) combined with carboplatin and etoposide is used as the first-line treatment for patients with extensive small cell lung cancer (ES-SCLC).